PMID: 15230294Jul 3, 2004Paper

Cyclophosphamide: new approaches for systemic lupus erythematosus

Lupus
M Petri

Abstract

Cyclophosphamide remains the 'gold standard' treatment for severe organ threatening systemic lupus erythematosus (SLE), especially renal and central nervous system lupus. Intravenous and oral cyclophosphamide have been compared, retrospectively, with similar two year remission rates of 73% and 90%. In a meta-analysis, intravenous cyclophosphamide with oral prednisone is more effective than oral prednisone alone. The efficacy of cyclophosphamide in lupus nephritis has been proven in multiple clinical trials, but efficacy has to be balanced with toxicity, including infection, gonadal failure, and malignancy. Although the continued use ofcyclophosphamide for renal lupus has been challenged by a recent trial of mycophenolate mofetil, and may be challenged in the future by planned trials of biologics, it continues to be widely used. This review will touch on the traditional intravenous 'pulse' cyclophosphamide regimen, consider its toxicity, and contrast it with newer approaches to cyclophosphamide.

References

May 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A BediR J Jones
Apr 1, 1996·Annals of the Rheumatic Diseases·E M McDermott, R J Powell
Feb 1, 1997·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·V K Bansal, J A Beto
Feb 15, 1997·Annals of Internal Medicine·A MasalaE Bartoli
Feb 20, 1998·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·W A BriggsP J Scheel
Jun 2, 1998·Rheumatic Diseases Clinics of North America·M Petri
Aug 2, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·C C MokT C Au
Sep 5, 2002·Journal of Clinical Apheresis·Maria Giovanna DanieliGiovanni Danieli
Jan 16, 2003·Arthritis and Rheumatism·Michelle PetriRobert A Brodsky
Feb 19, 2003·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Peter PriftakisTina Dalianis

❮ Previous
Next ❯

Citations

Nov 1, 2006·Nature Clinical Practice. Rheumatology·Nikolay P NikolovGabor G Illei
Apr 30, 2008·The Journal of Experimental Medicine·Deborah L Smith-BouvierRhonda R Voskuhl
May 28, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Georg H StummvollPeter Biesenbach
May 25, 2006·Medicine·Nuntana KasitanonMichelle Petri
Nov 1, 2005·Current Opinion in Infectious Diseases·Gillian Barratt, Philippe Legrand
Nov 14, 2007·International Journal of Clinical Practice·J Ermann, B L Bermas
Nov 17, 2006·Annals of the Rheumatic Diseases·Mikiko TokunagaYoshiya Tanaka
Mar 5, 2013·The Journal of Clinical Investigation·Michael LookTarek M Fahmy
Apr 17, 2009·Journal of the American Society of Nephrology : JASN·Gerald B AppelUNKNOWN Aspreva Lupus Management Study Group
Oct 30, 2013·Nature Reviews. Rheumatology·Wen Xiong, Robert G Lahita
Mar 1, 2014·Clinical Rheumatology·Manuel F Ugarte-Gil, Graciela S Alarcón
Jan 1, 2012·Retinal Cases & Brief Reports·Jern Yee ChenGrant L Raymond
Jul 14, 2011·Psychology, Health & Medicine·Gabriëlle M N DaleboudtAd A Kaptein
Jan 6, 2006·Drug Metabolism Reviews·Jing ZhangYi-Zhun Zhu
Jun 26, 2008·Arthritis and Rheumatism·Kareem L GrahamPeggy P Ho
Dec 8, 2011·Journal of the American Academy of Nurse Practitioners·Marcia RobinsonLeanne M Currie
Sep 15, 2015·Current Opinion in Ophthalmology·Janine M PrebleC Stephen Foster
Mar 27, 2013·European Journal of Internal Medicine·Tobias BrummaierHerwig Pieringer
Aug 4, 2011·Clinical Journal of Oncology Nursing·Nancy Smith
Nov 26, 2014·Nature Reviews. Nephrology·Tak Mao Chan
May 8, 2003·Journal of the American Academy of Dermatology·Abdullah AlfadleyKhalid Al-Aboud
Apr 14, 2016·Einstein·Thelma Larocca SkareRenato Mitsunori Nisihara
Feb 14, 2017·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Biswanath BasuBinu George Babu
May 25, 2021·Saudi Journal of Biological Sciences·Adel F TohamyHassan A Hemeg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Current Opinion in Rheumatology
Bryan D Gescuk, John C Davis
Proceedings of the National Academy of Sciences of the United States of America
Emily C BaechlerTimothy W Behrens
Current Opinion in Rheumatology
Jim C Oates, Gary S Gilkeson
© 2022 Meta ULC. All rights reserved